ArticleThe Lancet. Infectious diseases2008
Funding of drugs: do vaccines warrant a different approach?
Article in The Lancet. Infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- A systematic review of health economic evaluations of vaccines in Brazil.Human vaccines & immunotherapeutics · 2017Pooled it
- Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.Human vaccines & immunotherapeutics · 2016Pooled it
- Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.PharmacoEconomics · 2016Pooled it
- Health economics of dengue: a systematic literature review and expert panel's assessment.The American journal of tropical medicine and hygiene · 2011Pooled it
- Strengthening the EU Health Technology Assessment Regulation: Integrating National Immunization Technical Advisory Groups for Comprehensive Vaccine Assessments.Journal of market access & health policy · 2025Article
- The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022).BMC public health · 2024Article
- The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.BMC medicine · 2023Article
- Determinants of basic childhood vaccination coverage in European and OECD countries.Human vaccines & immunotherapeutics · 2022Article
- Acceptance and application of a broad population health perspective when evaluating vaccine.Vaccine · 2022Article
- Realising the broader value of vaccines in the UK.Vaccine: X · 2021Article
- Article
- How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.Journal of market access & health policy · 2020Review
- Selection and Interpretation of Scientific Evidence in Preparation for Policy Decisions: A Case Study Regarding Introduction of Rotavirus Vaccine Into National Immunization Programs in Sweden, Norway, Finland, and Denmark.Frontiers in public health · 2018Article
- Rotavirus infection.Nature reviews. Disease primers · 2017Review
- What criteria do decision makers in Thailand use to set priorities for vaccine introduction?BMC public health · 2016Article
- Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?Applied health economics and health policy · 2016Article
- Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles.Journal of market access & health policy · 2016Article
- Differential time preferences for money and quality of life.PharmacoEconomics · 2014Article
- The sexual ethics of HPV vaccination for boys.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2014Article
- Drug versus vaccine investment: a modelled comparison of economic incentives.Cost effectiveness and resource allocation : C/E · 2013Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines have features that require special consideration when assessing their cost-effectiveness. These features are related to herd immunity, quality-of-life losses in young children, parental care and work loss, time preference, uncertainty, eradication, macroeconomics, and tiered pricing. Advisory committees on public funding for vaccines, or for pharmaceuticals in general, should be knowledgable about these special features. We discuss key issues and difficulties in decision making for vaccines against rotavirus, human papillomavirus, varicella-zoster virus, influenza virus, and Streptococcus pneumoniae. We argue that guidelines for economic evaluation should be reconsidered generally to recommend (1) modelling options for the assessment of interventions against infectious diseases; (2) a wider perspective to account for impacts on third parties, if relevant; (3) a wider scope of costs than health-care system costs alone, if appropriate; and (4) alternative discounting techniques to explore social time preference over long periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.